Advertisement

Annals of Surgical Oncology

, Volume 14, Issue 7, pp 2018–2027 | Cite as

Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor

  • Piotr RutkowskiEmail author
  • Zbigniew I. Nowecki
  • Wanda Michej
  • Maria Dębiec-Rychter
  • Agnieszka Woźniak
  • Janusz Limon
  • Janusz Siedlecki
  • Urszula Grzesiakowska
  • Michał Kąkol
  • Czesław Osuch
  • Marcin Polkowski
  • Stanisław Głuszek
  • Zbigniew Żurawski
  • Włodzimierz Ruka
Gastrointestinal Oncology

Abstract

Background

The introduction of adjuvant imatinib in gastrointestinal stromal tumors (GISTs) raised debate over the accuracy of National Institutes of Health risk criteria and the significance of other prognostic factors in GIST.

Methods

Tumor aggressiveness and other clinicopathological factors influencing disease-free survival (DFS) were assessed in 335 patients with primary resectable CD117-immunopositive GISTs (median follow-up, 31 months after primary tumor resection) from a prospectively collected tumor registry.

Results

Overall median DFS was 37 months, and estimated 5-year DFS was 37.8 %. In univariate analysis, high or intermediate risk group (P < .000001), mitotic index >5/50 high-power field (P < .00001), primary tumor size >5 cm (P < .00001), nongastric primary location (P = .0001), male sex (P = .01), R1 resection/tumor rupture (P = .0003), and epithelioid cell or mixed cell pathological subtype (P = .05) negatively affected DFS. In multivariate analysis, statistically significant factors negatively influencing DFS for model 1 were mitotic index >5/50 high-power field (P = .004), primary tumor size >5 cm (P = .001), male sex (P = .003), R1 resection/tumor rupture (P = .04), and nongastric primary tumor location (P = .02), and for model 2 were high/intermediate risk primary tumor (P < .0001 and P = .008, respectively), male sex (P = .007), resection R1/tumor rupture (P = .01), and nongastric primary tumor location (P = .02). Five-year DFS for high, intermediate, and low/very low risk group was 20%, 54%, and 96%, respectively.

Conclusions

The risk criteria for assessing the natural course of primary GISTs were validated, but additional independent prognostic factors—primary tumor location and sex—were also identified.

Keywords

Gastrointestinal stromal tumor Surgery Prognosis 

Notes

Acknowledgments

Supported by the Polish State Committee for Scientific Research, grant 3P05C05925. We thank all doctors devoted to GIST treatment and diagnosis who collaborated in the Polish Clinical GIST Registry, M. Rosinska for statistical advice, and J. Lasota (Armed Forces Institute of Pathology, Washington, DC) for critical remarks and mutational analyses data.

References

  1. 1.
    Kindblom LG, Remotti HE, Aldenborg F, Meis-Kinblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristic of the interstitial cell of Cajal. Am J Pathol 1998; 152:1259–69PubMedGoogle Scholar
  2. 2.
    Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1–12PubMedCrossRefGoogle Scholar
  3. 3.
    Trent JC, Benjamin RS. New developments in gastrointestinal stromal tumor. Curr Opin Oncol 2006; 18:386–95PubMedCrossRefGoogle Scholar
  4. 4.
    Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002; 33:459–65PubMedCrossRefGoogle Scholar
  5. 5.
    Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002; 38(Suppl 5):S39–51PubMedCrossRefGoogle Scholar
  6. 6.
    Miettinen M, El-Rifai W, Sobin LH, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal tumors: a review. Hum Pathol 2002; 33:478–83PubMedCrossRefGoogle Scholar
  7. 7.
    Eisenberg BL, Judson I. Surgery, imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol 2004; 11:465–75PubMedCrossRefGoogle Scholar
  8. 8.
    Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in pre-imatinib mesylate era. Cancer 2005; 103:821–9PubMedCrossRefGoogle Scholar
  9. 9.
    Debiec-Rychter M, Dumez H, et al. EORTC Soft Tissue and Bone Sarcoma Group. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004; 40:689–95PubMedCrossRefGoogle Scholar
  10. 10.
    Hosmer DW, Lemeshow S. Applied Survival Analysis: Regression Modeling of Time to Event Data. New York: J Wiley and Sons, 1999Google Scholar
  11. 11.
    DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000; 231:51–8PubMedCrossRefGoogle Scholar
  12. 12.
    Kim CJ, Day S, Yeh KA. Gastrointestinal stromal tumors: analysis of clinical and pathologic factors. Am Surg 2001; 67:135–7PubMedGoogle Scholar
  13. 13.
    Hinz S, Pauser U, Egberts JH, Schafmayer C, Tepel J, Fandrich F. Audit of a series of 40 gastrointestinal stromal tumour cases. Eur J Surg Oncol 2006; 32:1125–9PubMedCrossRefGoogle Scholar
  14. 14.
    Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg 2001; 136:383–9PubMedCrossRefGoogle Scholar
  15. 15.
    Ng E, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Ann Surg 1992; 215:68–77PubMedCrossRefGoogle Scholar
  16. 16.
    Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006; 202:623–9PubMedCrossRefGoogle Scholar
  17. 17.
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472–80PubMedCrossRefGoogle Scholar
  18. 18.
    Bucher P, Egger JF, Gervaz P, et al. An audit of surgical management of gastrointestinal stromal tumours (GIST). Eur J Surg Oncol 2006; 32:310–4PubMedCrossRefGoogle Scholar
  19. 19.
    Clary BM, Dematteo RP, Lewis JJ, et al. Gastrointestinal stromal tumors and leiomyosarcomas of the abdomen and retroperitoneum: a clinical comparison. Ann Surg Oncol 2001; 8:290–99PubMedCrossRefGoogle Scholar
  20. 20.
    Crosby JA, Catton CN, Davis A, et al. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 2001; 8:50–9PubMedCrossRefGoogle Scholar
  21. 21.
    Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001; 25:1121–33PubMedCrossRefGoogle Scholar
  22. 22.
    Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol .2004; 30:1098–103PubMedCrossRefGoogle Scholar
  23. 23.
    Bucher P, Taylor S, Villiger P, Morel P, Brundler MA. Are there any prognostic factors for small intestinal stromal tumors? Am J Surg 2004; 187:761–6PubMedCrossRefGoogle Scholar
  24. 24.
    Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005; 29:52–68PubMedCrossRefGoogle Scholar
  25. 25.
    Miettinen M, Kopczynski J, Makhlouf HR, et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol .2003; 27:625–41PubMedCrossRefGoogle Scholar
  26. 26.
    Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006; 30:477–89PubMedCrossRefGoogle Scholar
  27. 27.
    Kindblom LG, Meis KindBlom J, Bumming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST): a population based study of 600 cases. Ann Oncol 2003; 13:157Google Scholar
  28. 28.
    Buemming P, Meis-Kindblom JM, Kindblom LG, et al. Is there an indication for adjuvant treatment with imatinib mesylate in patients with aggressive gastrointestinal stromal tumors (GISTs)? (abstract 3289). Proc Am Soc Clin Oncol 2003; 22:818Google Scholar
  29. 29.
    Bumming P, Ahlman H, Andersson J, Meis-Kindblom JM, Kindblom LG, Nilsson B. Population-based study of the diagnosis and treatment of gastrointestinal stromal tumours. Br J Surg 2006; 93:836–43PubMedCrossRefGoogle Scholar
  30. 30.
    Emory TS, Sobin LH, Lukes L, Lee DH, O’Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23:82–7PubMedCrossRefGoogle Scholar
  31. 31.
    Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002; 20:3898–905PubMedCrossRefGoogle Scholar
  32. 32.
    Fujimoto Y, Nakanishi Y, Yoshimura K, Shimoda T. Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer 2003; 6:39–48PubMedCrossRefGoogle Scholar
  33. 33.
    Ueyama T, Guo KJ, Hashimoto H, et al. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer 1992; 69:947–55PubMedCrossRefGoogle Scholar
  34. 34.
    Andersson J, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006; 130:1573–81PubMedCrossRefGoogle Scholar
  35. 35.
    Kim TW, Lee H, Kang YK, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004; 10:3076–81PubMedCrossRefGoogle Scholar
  36. 36.
    Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59:4297–300PubMedGoogle Scholar
  37. 37.
    Corless CL, McGreevey L, Haley A, Twon A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002; 160:1567–72PubMedGoogle Scholar
  38. 38.
    Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813–25PubMedCrossRefGoogle Scholar
  39. 39.
    Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Sem Diagn Pathol 2006; 23:91–102CrossRefGoogle Scholar
  40. 40.
    Carillo R, Candia A, Rodriguez-Peralto JL, Caz V. Prognostic significance of DNA ploidy and proliferative index (MIB-1 index) in gastrointestinal stromal tumors. Hum Pathol 1997; 28:160–5CrossRefGoogle Scholar
  41. 41.
    Ozguc H, Yilmazlar T, Yerci O, et al. Analysis of prognostic and immunohistochemical factors in gastrointestinal stromal tumors with malignant potential. J Gastrointest Surg 2005; 9:418–29PubMedCrossRefGoogle Scholar
  42. 42.
    Cunningham RE, Federspiel BH, McCarthy WF, Sobin LH, O’Leary TJ. Predicting prognosis of gastrointestinal smooth muscle tumors. Role of clinical and histologic evaluation, flow cytometry, and image cytometry. Am J Surg Pathol 1993; 17:588–94PubMedCrossRefGoogle Scholar
  43. 43.
    Liu FY, Qi JP, Xu FL, Wu AP. Clinicopathological and immunohistochemical analysis of gastrointestinal stromal tumor. World J Gastroenterol 2006; 12:4161–5PubMedGoogle Scholar
  44. 44.
    Hu TH, Chuah SK, Lin JW, et al. Expression and prognostic role of molecular markers in 99 KIT-positive gastric stromal tumors in Taiwanese. World J Gastroenterol 2006; 12:595–602PubMedGoogle Scholar
  45. 45.
    Wong NA, Young R, Malcomson RD, et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003; 43:118–26PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2007

Authors and Affiliations

  • Piotr Rutkowski
    • 1
    Email author
  • Zbigniew I. Nowecki
    • 1
  • Wanda Michej
    • 2
  • Maria Dębiec-Rychter
    • 3
  • Agnieszka Woźniak
    • 4
  • Janusz Limon
    • 4
  • Janusz Siedlecki
    • 5
  • Urszula Grzesiakowska
    • 6
  • Michał Kąkol
    • 7
  • Czesław Osuch
    • 8
  • Marcin Polkowski
    • 9
  • Stanisław Głuszek
    • 10
  • Zbigniew Żurawski
    • 1
  • Włodzimierz Ruka
    • 1
  1. 1.Department of Soft Tissue/Bone Sarcoma and MelanomaM. Sklodowska-Curie Memorial Cancer Center and Institute of OncologyWarsawPoland
  2. 2.Department of PathologyM. Sklodowska-Curie Memorial Cancer Center and Institute of OncologyWarsawPoland
  3. 3.Center for Human GeneticsUniversity of LeuvenLeuvenBelgium
  4. 4.Department of Biology and GeneticsMedical University of GdanskGdanskPoland
  5. 5.Department of Molecular BiologyM. Sklodowska-Curie Memorial Cancer Center and Institute of OncologyWarsawPoland
  6. 6.Department of RadiologyM. Sklodowska-Curie Memorial Cancer Center and Institute of OncologyWarsawPoland
  7. 7.Regional Oncological CenterGdanskPoland
  8. 8.Department of General SurgeryJagiellonian UniversityCracowPoland
  9. 9.Department of GastroenterologyM. Sklodowska-Curie Memorial Cancer Center and Institute of OncologyWarsawPoland
  10. 10.City HospitalKielcePoland

Personalised recommendations